Syndax 10-Q: Q3 Revenue $83.3M, Net Loss Narrows to $49.4M, $551M Cash
SNDX is trading near its 52-week low of $12.795 (0.9% above the low).
Summary
Syndax's Q3 10-Q shows revenue of $83.3M (up 82%) and a narrower $49.4M net loss, with $551.1M in cash and investments. After the $250M convertible note and $344.1M royalty financing, the balance sheet now carries a $17.2M stockholders' deficit.
Key Events · Earnings and Guidance · SNDX
-
Q3 Revenue Jumps 82% to $83.3M
Total revenue of $83.3 million versus $45.9 million a year ago, split between $60.7 million of Revuforj product revenue and $22.6 million of Niktimvo collaboration revenue.
-
Net Loss Narrows to $49.4M
Net loss of $49.4 million, or $0.55 per share, improved from $60.7 million, or $0.70 per share, in the prior-year quarter; nine-month net loss was $141.5 million versus $217.4 million.
-
Cash and Investments of $551.1M
Cash, cash equivalents and short- and long-term investments totaled $551.1 million at September 30, 2026, against a $17.2 million stockholders' deficit.
-
Convertible Notes and Royalty Liability Weigh on Balance Sheet
The June 2026 $250.0 million 2.25% convertible notes (net $244.2 million) and the $344.1 million net Royalty Pharma liability drive total liabilities to $709.9 million.
Analysis · SNDX · Life Sciences
The 10-Q confirms the Q3 beat already flagged in today's 8-K, but the full balance sheet is the real story. Revenue is compounding—Q3 $83.3M, up 82%—while the net loss narrows to $49.4M from $60.7M, and $551.1M of cash plus investments funds operations well past the next two years of trial readouts. Against that, total stockholders' equity has flipped to a $17.2M deficit, driven by the $250M convertible notes issued in June and the $344.1M Royalty Pharma liability; leverage, not dilution, is now the balance-sheet constraint. The IPF failure of axatilimab (MAXPIRe) removes an optional upside catalyst but does not touch the two approved drugs.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNDX was trading at $12.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.80 to $25.59. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.